Archive for the 'Markets' Category
July 29th, 2010 by admin
Milestone payments are becoming an increasingly familiar aspect of many biotech deals, as buyers try to mitigate the risks inherent with big purchases. Take Celgene’s $2.9 billion buyout of Abraxis; the biotech giant set aside $650 million in milestone payments if Abraxis’ key drug Abraxane hit certain goals. “These structures are a great way for buyer and seller to share the risk that’s related to drug development,” says analyst Brett Skolnik. Milestones also encourage buyer and seller to look beyond the merger, making it more likely the deal will be beneficial to both sides in the long term.
Continue reading ‘Milestones Mitigate Risk in Biotech Deals’
July 28th, 2010 by admin
A Utah doctor is being sent to jail for his connection to an illegal online pharmacy that sold more than eight million weight-loss pills manufactured in Mexico. Dr James A Brinton was sentenced to three years in a federal penitentiary after he pleaded guilty to conspiracy to distribute phentermine and conspiracy to commit international money laundering, according to the Desert News. The doctor was one of 18 people who were charged with crimes in connection to the Lighthouse Meds website.
Continue reading ‘Utah Doctor Sentenced to Three Years for Illegal Online Pharmacy’
July 27th, 2010 by admin
Oncologics, lipid regulators, respiratory agents, antidiabetics and anti-ulcerants are the five largest drug classes by sales. But annual sales are only half the story. Which drug classes are booming, and which have plateaued–or even dropped? IMS Health has released top-line industry data revealing the 15 largest drug classes, and we’ve crunched the numbers to take a closer look at the average sales growth of the 15 largest therapeutic classes over the last five years.
Continue reading ‘Fastest Growing Therapeutic Classes (by Sales)’
July 26th, 2010 by admin
Eli Lilly (NYSE: LLY) is looking to its pipeline to fill the gaps left by a number of high-profile drugs coming off patent. In October 2011, blockbuster Zyprexa will fall to generic competition; additionally, about three-quarters of Lilly’s current revenue comes from eight drugs that will lose patent protection between now and 2017. ”We have the challenge of replenishing our product portfolio from our pipeline,” says CEO John Lechleiter in a USA Today interview. “Fortunately, we have the most exciting pipeline today in our history.”
Continue reading ‘Pipeline to Soften Lilly Patent Losses’
July 23rd, 2010 by admin
A group of scientists have demonstrated that specially engineered stem cells could be used to fights off AIDS, successfully testing the approach in mice engineered to develop immune systems similar to humans. The investigators started with the observation that a small group of people who are virtually immune to HIV have disabled CCR5 receptors on their immune cells–a door the virus uses to infect the cells. The scientists engineered stem cells with the ‘door’ essentially locked, then inserted them into the mice, where they developed into immune cells that were able to guard the mice against HIV.
Continue reading ‘Specially Engineered Immune Cells Ward off AIDS’
July 21st, 2010 by admin
Welcome to the annual look at the biggest CEO paychecks in the pharma industry. The major trend in 2009 was the mega-merger, which helped propel former Schering-Plough CEO Fred Hassan to the top of this year’s list. With the help of a $33 million golden handshake, Hassan bypassed perennial top dogs Bill Weldon (Johnson & Johnson) and Miles White (Abbott) as the highest-paid CEO in Pharma.
Continue reading ‘Top 10 Pharma CEO Salaries of 2009′
July 20th, 2010 by admin
In the quest for a cancer vaccine, Merck KGaA is again stepping into the ring. Vaximm Holding AG, the company’s joint venture with a Switzerland’s BB Biotech Ventures III, will start testing a therapeutic cancer vaccine in patients next year. The vaccine, VXM01, harnesses the body’s immune system to fight cancer by using T-cells to close off the tumor’s blood supply. Roche’s Avastin also focuses on the tumor’s blood supply, but it focuses on eliminating a protein that creates the blood vessels to the tumor.
Continue reading ‘Merck KGaA’s Pancreatic Cancer Vaccine Ready for Testing’
July 16th, 2010 by admin
Over the next five years, the market for biosimilars will swell to $10 billion, but only a handful of players with deep pockets and world-class R&D facilities will be able to play. And that means that most small- and medium-size drug developers will never have a chance of leaping into the new market for follow-on biologics.
Continue reading ‘Only the Biggest Developers can play the Biosimilar Game’
July 14th, 2010 by admin
Chang Lu and his chemical engineering research group at Virginia Tech have discovered how to “greatly enhance” the delivery of DNA payloads into cells. The description of their work will be featured on the cover of Lab on a Chip, the premier journal for researchers in microfluidics. Lu’s ultimate goal is to apply this technique to create genetically modified cells for cancer immunotherapy, stem cell therapy and tissue regeneration.
Continue reading ‘New Spin on DNA Delivery: Enhanced Delivery Method of DNA Payloads into Cells’
July 9th, 2010 by admin
For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it’s often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.
Continue reading ‘Scientists Grow New Lungs Using ‘Skeletons’ of Old Ones’
